Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by gregoooon Aug 30, 2012 5:07pm
211 Views
Post# 20281695

RE: 2ND QTR.

RE: 2ND QTR.

 

e) Shares for services agreements

Effective March 1, 2012, the Company entered into management agreements with two of its senior executives or companies for their services in performing the functions of President and Chief Executive Officer and Executive Chairman, respectively. For these services, each is entitled is entitled to compensation comprised of, among other things, such number of common shares (collectively, the "Shares for Services") of the Company equal to $1,000,000 divided by the Discounted Market Price (as such term is defined in the TSX Venture Exchange Corporate Finance Manual) on the date after certain company milestones have been reached and services have been provided. The issuance of the Shares for Services is subject to approval by the TSX Venture Exchange, who has further required that the shares be approved by the shareholders.

The milestone for the granting of the Shares for Services was achieved on May 31, 2102 with the successful drilling of the Flami-1 well. However, as the requisite shareholder approval has not been obtained, the individuals have agreed to defer their rights under their respective management agreements until a later date when shareholder approval can be obtained.

Bullboard Posts